Lavomax, 125 mg 3 pcs.

Low-molecular synthetic inducer of interferon that stimulates formation of all types of interferon in the body (alpha, beta, gamma and lambda).

The main producers of interferon in response to tiloron administration are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes.

After oral administration the maximum production of interferon is determined in the sequence intestine – liver – blood in 4-24 hours.

According to experimental data after single oral administration of Tiloron in dose equivalent to maximum daily dose for human the maximum concentration of interferon lambda in lung tissue is determined in 24 hours, of interferon alpha – in 48 hours.

Induction of interferon lambda in lung tissue increases antiviral protection of the respiratory tract during influenza and other respiratory viral infections.

In human leukocytes induces synthesis of interferon. Stimulates bone marrow stem cells, depending on the dose increases antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors and T-helpers.

Effective against various viral infections including flu viruses, other acute respiratory viral infections, hepatitis viruses and herpesviruses.

The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, resulting in inhibition of virus reproduction.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Compatible with antibiotics and agents of traditional treatment of viral and bacterial diseases.

Clinically significant interaction of Lavomax® with antibiotics and agents of traditional treatment of viral and bacterial diseases was not identified.

Special Instructions

Synopsis

Features

Contraindications

Side effects

Overdose

In cases of Lavomax® overdose are unknown.

Similarities